StreetInsider.com News Articles

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Tue, 18 Aug 2026 02:12:00 -0400

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix^® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

"This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma. "We look forward to continued collaboration with

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

Thu, 02 Jul 2026 07:12:00 -0400

LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026.

If you are interested in meeting with Hansa's management, please contact